CUREHUNTER Opens Research Interface Beta to Doctors Free of Charge and Revolutionizes Practice of Evidence Based Medicine in Real-Clinical-Time
Portland, OR (PRWEB) September 21, 2007 --
CUREHUNTER announces free physician access to its advanced Research Interface, enabling instant decision support evidence checks and facilitating the practice of Evidence Based Medicine. An introductory 5 min. screencast is available at http://www.curehunter.com/screencast/research . Physicians can register online at http://www.curehunter.com for free access.
Drug treatment options are becoming increasingly complex and costly, while patient adverse events are on the rise. Quality health care and safety issues, now more than ever, demand advanced expert systems and decision support software to facilitate choices grounded in peer-reviewed research.
While the demand for evidence-based practice is growing daily, doctors and the FDA are both overwhelmed with paperwork preventing them from reviewing the data pouring out of major professional journals.
While "information overload" is affecting most scientific disciplines, its immediate impact on human beings is seen daily in the physician's office. With over 200,000 new medical research articles being published each year, it is difficult for doctors to actually practice Evidence Based Medicine -- even though many in government, law, payer -- provider administration and clinical operations centers are demanding that they do so.
By automating meta-analysis of the medical literature in real time, CUREHUNTER brings physicians a powerful new tool to meet and exceed the primary goals of practical and applied Evidence Based Medicine: Improve safety, increase positive patient outcomes for first time prescriptions, minimize adverse events, and dramatically reduce recurring visits to change medications-a principal driver of additional tests and costs during follow up visits for patients who report their "medications aren't working" -- a number now estimated to be as high as 30% and adding billions to insurance costs.
CUREHUNTER leads the industry as the first to market with an Evidence Based Medicine (EBM) solution for physicians that self-authors comprehensive drug meta-analyses supporting those developed by panels of human experts-and does so in Real Clinical Time.
The foundation for all CUREHUNTER products, the CureHunter Discovery Engine, is an Artificial Intelligence-based medical text mining system trained to read the entire US National Library of Medicine Medline Archive and automatically extract the key evidence of successful clinical outcomes achieved by all known drugs and active biological agents for 99% of known human diseases.
The Web2.0 Research Interface enables doctors anywhere in the world to find the best treatment options available in seconds-just by entering any disease's name in a simple Google-like search field. The relative drug performance results graphed on screen are grounded directly in the peer-reviewed research and fully sourced-down to exact statements of efficacy-with references and abstracts.
CUREHUNTER's data extraction, final accuracy, quantification, testability and automatically documented data audit trail distinguish it from "Black Box" systems that don't show the specific references for their conclusions.
CUREHUNTER goes beyond search engines that return thousands of links to what "might be useful information". The CureHunter Research Interface cuts through search engine "line noise" and only returns distinctly relevant information, quantifying it such that the efficacy of each treatment option is immediately apparent.
Pricing and Availability
For more CureHunter Research Interface product information, including a list of officially supported systems and authorized partners, please visit: http://www.curehunter.com
CUREHUNTER is headquartered in Portland, OR and has offices in Tokyo, Japan. For more information, visit http://www.curehunter.com
Going forward, CUREHUNTER will continue to revolutionize the medical information market for consumers, clinicians and pharmaceutical research scientists. The Company will continue to create innovative, industry-changing products for pharmaceutical drug discovery and development, consumers seeking unbiased objective medication evidence, and contribute to the wide availability of scientific data on mobile devices.